Human TGF-alpha Quantikine ELISA Kit
| Name | Human TGF-alpha Quantikine ELISA Kit |
|---|---|
| Supplier | R&D Systems |
| Catalog | DTGA00 |
| Category | ELISA Kit |
| Prices | $509.00 |
| Sizes | 1 kit |
| Assay Type | Solid Phase Sandwich ELISA |
| Sample Type | Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL), Human Milk (50 uL) |
| Sensitivity | 7.1 pg/mL |
| Range | 15.6 - 1,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Human Milk) |
| Format | 96-well strip plate |
| Applications | ELISA |
| Species Reactivities | Human |
| Description | The Quantikine Human TGF-alpha Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human TGF-alpha in cell culture supernates, serum, plasma, and human milk |
| Gene | TGFA |
| Supplier Page | Shop |
Product images
Product References
Circulating hepatocyte growth factor is correlated with resistance to cetuximab - Circulating hepatocyte growth factor is correlated with resistance to cetuximab
Yonesaka K, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K. Anticancer Res. 2015 Mar;35(3):1683-9.
DUOX-Mediated Signaling Is Not Required for LPS-Induced Neutrophilic Response in - DUOX-Mediated Signaling Is Not Required for LPS-Induced Neutrophilic Response in
Chang S, Linderholm A, Harper R. PLoS One. 2015 Jul 6;10(7):e0131810.
Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and - Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and
Zhang Z, Dong Z, Lauxen IS, Filho MS, Nor JE. Cancer Res. 2014 May 15;74(10):2869-81.
Activation of HER family signaling as a mechanism of acquired resistance to ALK - Activation of HER family signaling as a mechanism of acquired resistance to ALK
Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K. Clin Cancer Res. 2012 Nov 15;18(22):6219-26.
ETS-1 oncogenic activity mediated by transforming growth factor alpha. - ETS-1 oncogenic activity mediated by transforming growth factor alpha.
Holterman CE, Franovic A, Payette J, Lee S. Cancer Res. 2010 Jan 15;70(2):730-40.
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 - Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. Br J Cancer. 2009 Jan 27;100(2):298-304.
Molecular response to cetuximab and efficacy of preoperative cetuximab-based - Molecular response to cetuximab and efficacy of preoperative cetuximab-based
Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O, De Moor B, Tejpar S, McBride WH, Penninckx F, Scalliet P, Stroh C, Vlassak S, Sempoux C, Machiels JP. J Clin Oncol. 2009 Jun 10;27(17):2751-7.
RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma - RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma
Kreeger PK, Mandhana R, Alford SK, Haigis KM, Lauffenburger DA. Cancer Res. 2009 Oct 15;69(20):8191-9.
Cross-talk between estrogen receptor and epidermal growth factor receptor in head - Cross-talk between estrogen receptor and epidermal growth factor receptor in head
Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP. Clin Cancer Res. 2009 Nov 1;15(21):6529-40.
Epidermal growth factor receptor blockade in combination with conventional - Epidermal growth factor receptor blockade in combination with conventional
Ren W, Korchin B, Zhu QS, Wei C, Dicker A, Heymach J, Lazar A, Pollock RE, Lev D. Clin Cancer Res. 2008 May 1;14(9):2785-95.